scholarly article | Q13442814 |
P356 | DOI | 10.1017/S0033291700049047 |
P698 | PubMed publication ID | 7156248 |
P2093 | author name string | McQueen JK | |
Yates CM | |||
Thomson J | |||
Ashcroft GW | |||
Rankin H | |||
Cummings SW | |||
P2860 | cites work | Depressive Illness in a General Practice. A Demographic Study and a Controlled Trial of Imipramine | Q54288068 |
Amine Precursors and Depression | Q66891826 | ||
Amitriptyline plasma concentration and clinical response | Q66904585 | ||
Plasma Tryptophan Concentration in Depressive Illness and Mania | Q67437906 | ||
Letter: Tryptophan and depression | Q67474841 | ||
The Comparative Antidepressant Value of L-Tryptophan and Imipramine With and Without Attempted Potentiation by Liothyronine | Q69158742 | ||
l-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects | Q69330802 | ||
Treatment of depression in general practice | Q69499660 | ||
Studies of Alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in Depression and Mania | Q69926431 | ||
Sequential comparison of L-tryptophan with E.C.T. in severe depression | Q70134580 | ||
Plasma concentration of amitriptyline and clinical response | Q93723513 | ||
A rating scale for depression | Q24564540 | ||
Multiple Range and Multiple F Tests | Q26778372 | ||
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan | Q34519645 | ||
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study | Q34552567 | ||
Letter: Tryptophan/imipramine in depression | Q39354850 | ||
Amitriptyline plasma-concentration and clinical effect. A World Health Organisation Collaborative Study | Q39471857 | ||
Affective disorder: studies with amine precursors | Q41066531 | ||
Amitriptyline plasma levels and therapeutic response | Q44990657 | ||
The daily rhythm of plasma tryptophan and tyrosine in depression | Q48418035 | ||
Total and free tryptophan concentration in the plasma of depressive patients | Q48643863 | ||
Potentiation of the antidepressant action of clomipramine by tryptophan | Q51290103 | ||
Comparative trial of L-tryptophan and amitriptyline in depressive illness | Q51290187 | ||
Controlled trial of amitriptyline in general practice. | Q51326588 | ||
A specific gas-chromatographic method for the measurement of “steady-state” plasma levels of amitriptyline and nortriptyline in patients | Q52121640 | ||
Tryptophan in the treatment of depression. | Q53785422 | ||
Total and non-bound tryptophan in unipolar illness | Q53801700 | ||
Comparative trial of L-tryptophan and E.C.T. in severe depressive illness. | Q53995007 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | amitriptyline | Q58397 |
tryptophan | Q181003 | ||
placebo | Q269829 | ||
P304 | page(s) | 741-751 | |
P577 | publication date | 1982-11-01 | |
P1433 | published in | Psychological Medicine | Q7256364 |
P1476 | title | The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo | |
P478 | volume | 12 |
Q49063210 | A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients |
Q51091869 | A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. |
Q38969500 | Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale |
Q42454498 | Alpha-lactalbumin-enriched diets enhance serotonin release and induce anxiolytic and rewarding effects in the rat. |
Q24202486 | Amitriptyline versus placebo for major depressive disorder |
Q24239979 | Antidepressants versus placebo for depression in primary care |
Q52877703 | Antidepressive effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. |
Q34155549 | Anxiety, depression, and insomnia |
Q35327958 | Cancer patients' perspectives on discontinuing depression treatment: the "drop out" phenomenon |
Q42764855 | Childhood mortality after high dose vitamin A |
Q34729005 | Cognitive behavioral therapy and mindfulness-based cognitive therapy for depressive symptoms in patients with diabetes: design of a randomized controlled trial |
Q43697742 | Diagnosis of depression by primary care physicians versus a structured diagnostic interview. Understanding discordance |
Q35237343 | Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice |
Q24187378 | Drugs versus placebo for dysthymia |
Q24246945 | Drugs versus placebo for dysthymia |
Q35823058 | Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks |
Q48819884 | Effects of Tryptophan 2,3-Dioxygenase Inhibitors in the Rat |
Q34629445 | Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis |
Q41483596 | Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice |
Q35657945 | Exogenous Tryptophan Promotes Cutaneous Wound Healing of Chronically Stressed Mice through Inhibition of TNF-α and IDO Activation |
Q24678618 | How to increase serotonin in the human brain without drugs |
Q39750057 | Indoleamines in depression and suicide |
Q48376896 | Inhibition of restraint-induced anorexia by injected tryptophan |
Q34011523 | L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. |
Q38157695 | L-Tryptophan: Biochemical, nutritional and pharmacological aspects |
Q33553831 | Managing depression in primary care |
Q33569696 | Measuring quality of life in patients with depression or anxiety |
Q52051208 | Mental health intervention programs in primary care: their scientific basis |
Q71826428 | Moclobemide Versus Clomipramine in Depressed Patients in General Practice. A Randomized, Double-Blind, Parallel, Multicenter Study |
Q77071546 | Modelling the cost effectiveness of antidepressant treatment in primary care |
Q48664579 | Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts |
Q37788635 | Possible roles of excess tryptophan metabolites in cancer |
Q39540950 | Primary care patients' opinions regarding the importance of various aspects of care for depression |
Q36902430 | Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care |
Q35608339 | Recognition and management of depression in general practice: consensus statement |
Q41690277 | Serotonergic systems |
Q85889587 | Solid tryptophan as a pseudoracemate: physicochemical and crystallographic characterization |
Q38806660 | TDO as a therapeutic target in brain diseases |
Q40891949 | The effect of carbohydrates on affect |
Q30985038 | The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials |
Q43799861 | The metabolic fate of infused L-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites |
Q34558852 | The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels |
Q34611434 | The role of vitamins and minerals in psychiatry |
Q90169426 | Therapeutic Duration and Extent Affect the Effect of Moxibustion on Depression-Like Behaviour in Rats via Regulating the Brain Tryptophan Transport and Metabolism |
Q34592227 | Treatment non-adherence in affective disorders. |
Q42764825 | Treatment of depression in primary care |
Q47640895 | Tryptophan supplementation and serotonin function: genetic variations in behavioural effects. |
Q40317269 | Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers |
Q36986106 | Use of tryptophan in combination with other antidepressant treatments: a review |
Q67771544 | Which antidepressant? |
Search more.